Literature DB >> 19851718

Mice lacking multidrug resistance protein 1a show altered dopaminergic responses to methylenedioxymethamphetamine (MDMA) in striatum.

Karl B Scheidweiler1, Bruce Ladenheim, Jean Lud Cadet, Marilyn A Huestis.   

Abstract

Multidrug resistance protein 1a (MDR1a) potentiated methylenedioxymethamphetamine (MDMA)-induced decreases of dopamine (DA) and dopamine transport protein in mouse brain one week after MDMA administration. In the present study, we examined if mdr1a wild-type (mdr1a +/+) and knock-out (mdr1a -/-) mice differentially handle the acute effects of MDMA on the nigrostriatal DA system 0-24 h following a single drug injection. 3-way ANOVA revealed significant 2-way interactions of strain x time (F (5,152) = 32.4, P < 0.001) and strain x dose (F (3,152) = 25.8, P < 0.001) on 3,4-dihydroxyphenylacetic acid (DOPAC)/DA ratios in mdr1a +/+ and -/- mice. 0.3-3 h after 10 mg/kg MDMA, DOPAC/DA ratios were increased in mdr1a +/+ mice, but decreased 0.3-1 h after MDMA in mdr1a -/- mice. Twenty-four hours after 10 mg/kg MDMA, DOPAC/DA ratios were increased 600% in mdr1a +/+ mice compared to saline-treated control mice, while in mdr1a -/- mice DOPAC/DA ratios were unchanged. Striatal MDMA and its metabolite, methylenedioxyamphetamine, concentrations by gas chromatography-mass spectrometry were similar in both strains 0.3-4 h after MDMA, discounting the role of MDR1a-facilitated MDMA transport in observed inter-strain differences. Increased DOPAC/DA turnover in mdr1a +/+ mice following MDMA is consistent with the previous report that MDMA neurotoxicity is increased in mdr1a +/+ mice. Increased DA turnover via monoamine oxidase in mdr1a +/+ vs -/- mice might increase exposure to neurotoxic reactive oxygen species.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19851718      PMCID: PMC2917895          DOI: 10.1007/s12640-009-9124-z

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  59 in total

1.  Inhibitory glutamatergic regulation of evoked dopamine release in striatum.

Authors:  Y Wu; S M Pearl; M J Zigmond; A C Michael
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

2.  Expression profiling of osteosarcoma cells transfected with MDR1 and NEO genes: regulation of cell adhesion, apoptosis, and tumor suppression-related genes.

Authors:  Marta Sanchez-Carbayo; Thomas J Belbin; Katia Scotlandi; Michael Prystowsky; Nicola Baldini; Geoffrey Childs; Carlos Cordon-Cardo
Journal:  Lab Invest       Date:  2003-04       Impact factor: 5.662

3.  Amphetamine-induced toxicity in dopamine terminals in CD-1 and C57BL/6J mice: complex roles for oxygen-based species and temperature regulation.

Authors:  I N Krasnova; B Ladenheim; S Jayanthi; J Oyler; T H Moran; M A Huestis; J L Cadet
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

4.  Non-linear pharmacokinetics of MDMA ('ecstasy') in humans.

Authors:  R de la Torre; M Farré; J Ortuño; M Mas; R Brenneisen; P N Roset; J Segura; J Camí
Journal:  Br J Clin Pharmacol       Date:  2000-02       Impact factor: 4.335

5.  Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity.

Authors:  J Paul Hansen; Evan L Riddle; Verónica Sandoval; Jeffrey M Brown; James W Gibb; Glen R Hanson; Annette E Fleckenstein
Journal:  J Pharmacol Exp Ther       Date:  2002-03       Impact factor: 4.030

6.  Catechol O-methyltransferase mRNA expression in human and rat brain: evidence for a role in cortical neuronal function.

Authors:  M Matsumoto; C Shannon Weickert; M Akil; B K Lipska; T M Hyde; M M Herman; J E Kleinman; D R Weinberger
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

Review 7.  The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").

Authors:  A Richard Green; Annis O Mechan; J Martin Elliott; Esther O'Shea; M Isabel Colado
Journal:  Pharmacol Rev       Date:  2003-07-17       Impact factor: 25.468

Review 8.  Impact of psychostimulants on vesicular monoamine transporter function.

Authors:  Annette E Fleckenstein; Glen R Hanson
Journal:  Eur J Pharmacol       Date:  2003-10-31       Impact factor: 4.432

9.  P-glycoprotein modulation by the designer drugs methylenedioxymethamphetamine, methylenedioxyethylamphetamine and paramethoxyamphetamine.

Authors:  Nahal Ketabi-Kiyanvash; Johanna Weiss; Walter Emil Haefeli; Gerd Mikus
Journal:  Addict Biol       Date:  2003-12       Impact factor: 4.280

10.  Protection against 3,4-methylenedioxymethamphetamine-induced neurodegeneration produced by glutathione depletion in rats is mediated by attenuation of hyperthermia.

Authors:  Esther O'Shea; N Easton; J R Fry; A R Green; C A Marsden
Journal:  J Neurochem       Date:  2002-05       Impact factor: 5.372

View more
  1 in total

1.  Effects of 3,4-methylenedioxymethamphetamine (MDMA) and its main metabolites on cardiovascular function in conscious rats.

Authors:  Charles W Schindler; Eric B Thorndike; Bruce E Blough; Srihari R Tella; Steven R Goldberg; Michael H Baumann
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.